When AI Ate the Funding: What's Left for MedTech Founders?

​Capital that once flowed steadily into MedTech has slowed to a trickle, while AI startups keep raising record rounds. If you're building in diagnostics, devices, digital health, or health IT and wondering where the money went (and how to get your share of what's left), you're not alone. Carl Becker, Schooner Capital and I, Bob Garces, Boston Harbor Angels, will lead a Roundtable discussion on this subject matter on September 11.

​Join Sbur's MedTech Group, a gathering of founders and investors across the space — from imaging and surgical robotics to remote monitoring, SaMD, and healthcare IT — meeting every Friday afternoon (virtual or in-person) to trade insights, resources, and warm introductions that open doors to capital, customers, and partnerships. As a member, you can pick a topic and lead the group discussion.

​This Session: Navigating the MedTech Funding Drought We'll unpack why capital has shifted so heavily toward AI, what that means for MedTech valuations and deal terms right now, and, most importantly, what founders in the room are actually doing to stay funded: alternative capital sources, strategic partnerships, revenue-first strategies, and how investors are still finding conviction in this space despite the headwinds.

​Why You Should Be in the Room This isn't a panel. It's a working session with people facing the exact same pressures you are. Founders will leave with tactics they can use this quarter. Investors will leave with sharper pattern-recognition on where real opportunity still exists in MedTech.

​Seats are capped at 15 to keep the conversation genuinely interactive. RSVP to request your seat.